Role of positron emission tomography in lymphoma

Journal of Clinical Oncology

Volumn 23, Issue 21, 2005, Pages 4577-4580

  Juweid, Malik E ^a   Cheson, Bruce D ^b  

^a UNIVERSITY OF IOWA   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GROWTH FACTOR; DIAGNOSTIC AGENT;

DIAGNOSTIC ACCURACY; EDITORIAL; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT INDICATION; LYMPHOMA; METHODOLOGY; NOTE; SCINTISCANNING;

FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; POSITRON-EMISSION TOMOGRAPHY;

EID: 23044453180     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.904     Document Type: Editorial

References (24)

1. 18Flurorodeoxyglucose uptake In PET distinguishes between indolent and aggressive non-Hodgkin's lymphomas. J Clin Oncol 23:4643-4651, 2005
2. Rodriguez M, Rehn S, Ahlstrom H, et al: Predicting malignancy grade with PET in non-Hodgkin's iymphoma. J Nucl Med 36:1790-1796, 1995
3. Lapela M, Leskinen S, Minn HR, et al: Increased glucose metabolism in untreated non-Hodgkin's lymphoma: A study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 86:3522-3527, 1995
4. Leskinen-Kallio S, Ruotsalainen U, Nagren K, et al: Uptake of C-11 methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study. J Nucl Med 32:1211-1218, 1991
5. Hoekstra CJ, Paglianiti I, Hoekstra OS, et al: Monitoring response to therapy in cancer using [F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: An overview of different quantitative methods. Eur J Nucl Med 27:731-743, 2000
6. Okada J, Yoshikawa K, Itami M, et al: Positron emission tomography using fluorine-18 fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity. J Nucl Med 33:325-329, 1992
7. Yap CS, Schiepers C, Emmanouilides C, et al: Relationship between Ki-67 expression, a marker of tumor cell proliferation and glycolytic activity of lymphoma tissue. J Nucl Med 44.189P, 2003 (abstr 615)
8. 18F-FDG. J Nucl Med 44:1426-1431, 2003
9. 18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine model and in the human disease. Cancer Res 63:2681-2687, 2003
10. 18F-FDG for staging and grading of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 31:338, 2004 (abstr P203; suppl 2)
11. Hoh CK, Glaspy J, Rosen P, et al: Whole-body FDG-PET for staging of Hodgkin's disease and lymphoma. J Nucl Med 38:343-348, 1997
12. Moog F, Bangerter M, Diederichs CG, et al: Lymphoma: Role of whole-body 2-deoxy-2 [F-18] fluoro-D-glucose (FDG) PET in nodal staging. Radiology 203:795-800, 1997
13. 18F-FDG- PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 20:13-20, 1999
14. Horning S, Weller E, Kim KM, et al: Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol 22:3032-3038, 2004
15. Canellos GP: Residual mass in lymphoma may not be residual disease. J Clin Oncol 6:931-933, 1988
16. 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429-433, 1999
17. 18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncoi 19:414-419, 2001
18. Juweid ME, Wiseman GA, Vose JM, et al: Response assessment of aggressive non-Hodgkin's lymphoma by Integrated International Workshop criteria and fiuonne-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23:10.1200/JCO.2005.01.891
19. Jerusalem G, Beguin Y, Fassotte MF, et al: Early detection of relapse by whole-body emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 14:123-130, 2003
20. Römer W, Hanauske A-R, Ziegler S, et al: Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 91:4464-4471, 1998
21. Kostakoglu L, Coleman M, Leonard JP, et al: PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nuci Med 43:1018-1027, 2002
22. 18F]FDG) predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 13:1356-1363, 2002
23. Allen-Auerbach M, Quon A, Weber WA, et al: Comparison between 2-deoxy-2-[(18)F]fluoro-D-glucose positron-emission tomography and positron-emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 6:411-416, 2004
24. Freudenberg LS, Antoch G, Schutt P, et al: FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 31:325-329, 2004